# Geoffrey von Maltzahn

> Geoffrey von Maltzahn is a Series B investor at Flagship Pioneering backing Medical. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Flagship Pioneering](https://shizune.co/investors/profile/flagship-ventures)
- Location: Cambridge, United States
- Total investments: 1
- Last investment: Nov 2021
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/geoffrey-von-maltzahn-7a6b755a/
- Website: http://www.indigoag.com/

Geoffrey von Maltzahn is a Series B investor at Flagship Pioneering in Cambridge focused on Medical and Health Care. Geoffrey von Maltzahn is Co-Founder, Chief Executive Officer, and Director of Tessera Therapeutics, as well as a General Partner at Flagship Pioneering, where he focuses on inventing technologies and starting companies to address global challenges in medicine and environmental sustainability. He is also a co-founder of Sana Biotechnology, IndigoAgriculture, Kaleido Biosciences (NASDAQ:KLDO), Seres Therapeutics (NASDAQ:MCRB), Axcella Health (NASDAQ:AXLA), Generate Biomedicines, and others.Geoffrey currently serves as Chief Executive Officer and Director of Generate Biomedicines, Chief Innovation Officer and Director of Indigo, and Director of Kaleido Biosciences and Sana Biotechnology. He recently served as Chief Executive Officer of Cobalt Biomedicine, which he led from inception to merger with Sana Biotechnology, and as Kaleido’s Chief Executive Officer, where he led the company from inception to launching multiple clinical studies. Geoffrey also served as Chief Executive Officer of Indigo, where he led the development of the company’s technology platform and the discovery of the company’s first commercial products. Previously, Geoffrey was the Chief Technology Officer of Seres Therapeutics, where he led the discovery of SER-109 and built out the company’s discovery platform.Geoffrey has been recognized with numerous patent grants, awards, and publications. He is listed as an inventor on over 200 patent applications and patents, and he has co-authored more than 20 peer-reviewed articles. Geoffrey has received a number of awards and honors, including Bloomberg 50's Ones to Watch; Business Insider’s 30 Biotech Leaders Under 40; Endpoints 20 Biopharma Leaders Under 40; Boston Chamber of Commerce Ten Outstanding Young Leaders; the prestigious Lemelson-MIT Student Prize, awarded to the most innovative students at MIT; the National Inventors Hall of Fame Graduate Student Prize; the Biomedical Engineering Society Graduate Research Award; and the Harvard-MIT Martha Gray Prize. Geoffrey and his inventions have been profiled by Forbes, The Economist, CNN, Scientific American, Bloomberg Businessweek, Popular Science, MIT Technology Review, and other media.Geoffrey was awarded a PhD in biomedical engineering and medical physics from MIT under the mentorship of Sangeeta N. Bhatia, MD, PhD; an MS in bioengineering from the University of California, San Diego; and an SB in chemical engineering from MIT.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 100% |
| Health Care | 1 | 100% |
| Biotechnology | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Generate Biomedicines | Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines. | $370M | Series B | Nov 18, 2021 |  |

1 of 1 investments shown.

## Co-investors
- [Abu Dhabi Investment Authority](https://shizune.co/investors/profile/abu-dhabi-investment-authority) — VC Fund, 1 deal together
- [Alaska Permanent Fund](https://shizune.co/investors/profile/alaska-permanent-fund) — VC Fund, 1 deal together
- [Altitude Life Science Ventures](https://shizune.co/investors/profile/altitude-life-science-ventures) — VC Fund, 1 deal together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 1 deal together
- [Fidelity](https://shizune.co/investors/profile/fidelity-investments) — VC Fund, 1 deal together
- [Fidelity](https://shizune.co/investors/profile/fidelity-management-and-research-company) — VC Fund, 1 deal together

## About Flagship Pioneering

VC Fund · Cambridge, United States

Flagship Pioneering conceives, creates, resources, and grows first-in-category ventures to transform human health and sustainability. The company accelerates Flagship Pioneering’s advances in biology, engineering, medicine, energy, and beyond. The firm harnesses science and entrepreneurialism to envision alternative futures, beginning withseemingly unreasonable propositions and navigating to transformational outcomes through an evolutionary methodology.Flagship Pioneering combines innovative capacity, entrepreneurial leadership, and professional capital management in a single enterprise that systematically produces first-in-category companies.

5 contacts available at Flagship Pioneering.

| Name | Title | Profile |
| --- | --- | --- |
| Geoffrey von Maltzahn | General Partner | https://shizune.co/investors/profile/geoffrey-von-maltzahn |
| Hari Pujar | Operating Partner | https://shizune.co/investors/profile/hari-pujar |
| Thomas de Vlaam | Co-Founder FL86 | https://shizune.co/investors/profile/thomas-de-vlaam |
| Avak Kahvejian | General Partner | https://shizune.co/investors/profile/avak-kahvejian |
| Bill Johnson | Vice President of Finance | https://shizune.co/investors/profile/bill-johnson |

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Geoffrey von Maltzahn invest in?

Geoffrey von Maltzahn invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B stage. Most of the 1 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Geoffrey von Maltzahn last invest?

The most recent investment recorded for Geoffrey von Maltzahn closed in Nov 2021. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co